BMJ:眼睑局部浸润性鳞状细胞癌-案例报道

2016-01-14 Mechront 译 MedSci原创

患者女,82岁,因“发现右上眼睑肿块3+月”就诊。起初她的家庭医生认为该肿块是受感染的眼睑囊肿,并使用抗生素软膏进行治疗。期间患者并没有注意到肿块的快速增长,等发现肿块已经比之前变得更大的时候,患者通知了家庭医生,并进行了紧急转诊。查体示:占据了大部分右上睑的较大溃疡肿块,导致睫毛和眼睑组织受到破坏。如下图:(图片来自BMJ)病损处取组织进行活检示:局部浸润性鳞状细胞癌(SCC)。鳞状细胞癌是一种

患者女,82岁,因“发现右上眼睑肿块3+月”就诊。

起初她的家庭医生认为该肿块是受感染的眼睑囊肿,并使用抗生素软膏进行治疗。期间患者并没有注意到肿块的快速增长,等发现肿块已经比之前变得更大的时候,患者通知了家庭医生,并进行了紧急转诊。

查体示:占据了大部分右上睑的较大溃疡肿块,导致睫毛和眼睑组织受到破坏。

如下图:


(图片来自BMJ)

病损处取组织进行活检示:局部浸润性鳞状细胞癌(SCC)。

鳞状细胞癌是一种表皮恶性肿瘤,虽然眼睑部发生基底细胞癌的可能性是SCC的40倍,但SCC更具有局部侵袭性,常会迅速蔓延,造成周围组织结构的破坏,淋巴结转移风险也更大。

原始出处:

Ali Hassan,Paul Baddeley.Rapidly enlarging eyelid lesion.BMJ 2016;352:i21

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1978430, encodeId=2aff19e843028, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Nov 15 02:30:00 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684084, encodeId=160e16840849b, content=<a href='/topic/show?id=bf59e2814cf' target=_blank style='color:#2F92EE;'>#眼睑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72814, encryptionId=bf59e2814cf, topicName=眼睑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d8928034409, createdName=zhangbaojun, createdTime=Sun Mar 20 12:30:00 CST 2016, time=2016-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847867, encodeId=b61a184e8672b, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Tue May 17 06:30:00 CST 2016, time=2016-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405687, encodeId=7c4c140568eb8, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Sat Jan 16 05:30:00 CST 2016, time=2016-01-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1978430, encodeId=2aff19e843028, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Nov 15 02:30:00 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684084, encodeId=160e16840849b, content=<a href='/topic/show?id=bf59e2814cf' target=_blank style='color:#2F92EE;'>#眼睑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72814, encryptionId=bf59e2814cf, topicName=眼睑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d8928034409, createdName=zhangbaojun, createdTime=Sun Mar 20 12:30:00 CST 2016, time=2016-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847867, encodeId=b61a184e8672b, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Tue May 17 06:30:00 CST 2016, time=2016-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405687, encodeId=7c4c140568eb8, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Sat Jan 16 05:30:00 CST 2016, time=2016-01-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1978430, encodeId=2aff19e843028, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Nov 15 02:30:00 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684084, encodeId=160e16840849b, content=<a href='/topic/show?id=bf59e2814cf' target=_blank style='color:#2F92EE;'>#眼睑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72814, encryptionId=bf59e2814cf, topicName=眼睑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d8928034409, createdName=zhangbaojun, createdTime=Sun Mar 20 12:30:00 CST 2016, time=2016-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847867, encodeId=b61a184e8672b, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Tue May 17 06:30:00 CST 2016, time=2016-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405687, encodeId=7c4c140568eb8, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Sat Jan 16 05:30:00 CST 2016, time=2016-01-16, status=1, ipAttribution=)]
    2016-05-17 gaoxiaoe
  4. [GetPortalCommentsPageByObjectIdResponse(id=1978430, encodeId=2aff19e843028, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Nov 15 02:30:00 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684084, encodeId=160e16840849b, content=<a href='/topic/show?id=bf59e2814cf' target=_blank style='color:#2F92EE;'>#眼睑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72814, encryptionId=bf59e2814cf, topicName=眼睑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d8928034409, createdName=zhangbaojun, createdTime=Sun Mar 20 12:30:00 CST 2016, time=2016-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847867, encodeId=b61a184e8672b, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Tue May 17 06:30:00 CST 2016, time=2016-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405687, encodeId=7c4c140568eb8, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Sat Jan 16 05:30:00 CST 2016, time=2016-01-16, status=1, ipAttribution=)]
    2016-01-16 chg122